Core Insights - Peijia Medical-B (9996.HK) experienced a stock price increase of 8.26% to HKD 6.29, reaching a nearly two-month high since October 21 [1] - The company announced the approval of its TaurusTrio™ Transcatheter Aortic Valve (TAV) system by the National Medical Products Administration of China, with expectations for a successful market launch in China by December 11, 2025 [1] - The TaurusTrio™ TAV system aims to provide a safe and effective treatment option for Chinese patients suffering from severe aortic regurgitation (AR), addressing a significant unmet clinical need [1] - CEO and Chairman Zhang Yi has begun purchasing company shares in the open market since December 1, 2025, with a total investment not exceeding HKD 15 million, reflecting confidence in the company's intrinsic value and growth potential [1] Company Developments - The approval of the TaurusTrio™ TAV system is a significant milestone for Peijia Medical, as it seeks to fulfill a critical demand in the Chinese healthcare market [1] - Zhang Yi's share purchase indicates a strong belief in the company's future prospects and may signal potential further investments in the company [1]

Group 1 - The core viewpoint of the article highlights that Peijia Medical (9996.HK) experienced a significant stock price increase of 8.26%, reaching a new high of 6.29 HKD since October 21, indicating positive market sentiment [1] - Peijia Medical announced the approval of its TaurusTrio™ transcatheter aortic valve (TAV) system by the National Medical Products Administration of China, with expectations for successful market entry by December 11, 2025, addressing a major unmet clinical need for patients with severe aortic regurgitation (AR) in China [1] - The company's CEO and Chairman, Zhang Yi, has begun purchasing company shares in the open market since December 1, 2025, with a total investment not exceeding 15 million HKD, reflecting confidence in the company's intrinsic value and growth potential [1]

Core Viewpoint - Peijia Medical-B (09996) has received approval from the National Medical Products Administration of China for its TaurusTrio™ Transcatheter Aortic Valve (TAV) system, which is expected to address a significant unmet clinical need for patients with severe aortic regurgitation (AR) in China [1][5]. Group 1 - Peijia Medical's stock price increased by 7.06%, currently trading at HKD 6.22, with a transaction volume of HKD 7.6868 million [1][5]. - The TaurusTrio™ TAV system is developed and manufactured under an exclusive license from JenaValve Technology, Inc., based on the Trilogy™ Transcatheter Heart Valve (THV) system [1][5]. - The Trilogy™ THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial procedures in real-world clinical practice as of the announcement date [1][5]. Group 2 - The company anticipates that the successful launch of the TaurusTrio™ TAV system in China will provide a safe and effective treatment option for patients suffering from severe AR [1][5].